SCHEMBL2437609

SCHEMBL2437609

COC(=O)CCC(=O)Oc1cc(=O)n(C)c2ncc(I)cc12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 4/20 0.35
PDE3A Q14432 4/20 0.35
HSD17B10 Q99714 3/20 0.35
ALDH1A1 P00352 3/20 0.35
HTT P42858 3/20 0.35
MAPT P10636 2/20 0.35
LMNA P02545 2/20 0.35
KMT2A Q03164 1/20 0.35
KAT2B Q92831 4/20 0.34
SMN1; SMN2 Q16637 4/20 0.34
P2RY12 Q9H244 3/20 0.34
PDE2A O00408 2/20 0.33
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
TSHR P16473 1/20 0.32
CYP2C19 P33261 1/20 0.32
KDM4E B2RXH2 1/20 0.32
BRD4 O60885 1/20 0.32
TP53 P04637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2435402 0.75 EGLN1 (0.39) PDE3BPDE3AALDH1A1MAPTLMNA
SCHEMBL2577023 0.68 EGLN1 (0.44) TSHR
SCHEMBL2434416 0.66 ALDH1A1 (0.44) HSD17B10ALDH1A1HTTMAPTLMNA
SCHEMBL8924871 0.65 ALDH1A1 (0.47) PDE3BPDE3AHSD17B10ALDH1A1KMT2A
SCHEMBL2587838 0.63 L3MBTL1 (0.39) ALDH1A1HTTMAPTLMNAKMT2A
SCHEMBL17508975 0.62 HSD17B10 (0.46) PDE3BPDE3AHSD17B10ALDH1A1KMT2A
SCHEMBL22530365 0.61 KDM4E (0.47) ALDH1A1HTTMAPTCYP1A2CYP3A4
SCHEMBL2436829 0.60 HSD17B10 (0.33) HSD17B10HTTLMNAKMT2AHPGD
SCHEMBL3401213 0.57 TSHR (0.48) ALDH1A1HTTSMN1; SMN2TSHRHPGD
SCHEMBL17372802 0.57 CUL4A (0.37) HSD17B10ALDH1A1HTTMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2142509-B1 QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC (US) 2013-12-04 EP disclosed
US-8349868-B2 Azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2013-01-08 US disclosed
US-8048894-B2 Quinolones and azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2011-11-01 US disclosed
US-20110224248-A1 AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC. (US) 2011-09-15 US disclosed
EP-2142509-A2 QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE Amgen, Inc (US) 2010-01-13 EP disclosed
US-20090156605-A1 Quinolones and azaquinolones that inhbit prolyl hydroxylase AMGEN INC. (US) 2009-06-18 US disclosed
WO-2008130600-A2 QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC. (US) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156605-A1 Quinolones and azaquinolones that inhbit prolyl hydroxylase EGLN3, HIF1AN, EGLN2 PDE3B 713/4885PDE3A 686/4885HSD17B10 692/4885
US-20110224248-A1 AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE HIF1AN, EGLN3, EGLN2 PDE3B 543/4885PDE3A 492/4885HSD17B10 465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.